No Data
Huadong Medicine Gets Nod to Trial HDP-101 Drug
huadong medicine (000963.SZ): The clinical trial application for HDP-101 (HDM2027), developed through cooperation between China and the United States, has been approved.
On October 15, the huadong medicine (000963.SZ) announced that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine, recently received the "Drug Clinical Trial Approval Notice" (Notice No.: 2024LP02317) issued by the National Medical Products Administration (NMPA). The notice is for the development cooperation of HDP-101 by Zhongmei Huadong and the company's German joint venture Heidelberg Pharma AG (referred to as "Heidelberg Pharma").
Huadong Medicine targets infringement of "Suyan Zhen"! What's the deal with the confrontation of the two "Girl Needle" from a distance?
① “Yi Yanshi”, a subsidiary of Huadong Pharmaceutical, claims that Cai Cai Medical's “Su Yan Zhen” infringes on its invention patent rights and has now filed a civil lawsuit; ② Gu Yuchun, the parent company of Cai Cai Medical, has denied this claim. Up to now, “Su Yan Zhen” has been on the market for less than two months; ③ Industry insiders believe that it is now difficult to define whether Gu Yuchun is infringing.
Huadong Medicine's Units Get NMPA's Nod for Obesity Drug Clinical Trials
Huadong Medicine's (SZSE:000963) 7.2% CAGR Outpaced the Company's Earnings Growth Over the Same Five-year Period
Hong Kong stock abnormal | Chang Xin Biology-B (02509) rose more than 7%, achieving revenue of 44.919 million yuan in the first half of the year. Previously reached a cooperation with huadong medicine.
China Good Biotech-B (02509) rose more than 7%, as of the time of publication, it increased by 7.54%, closing at 24.95 Hong Kong dollars.
Fewer Investors Than Expected Jumping On Huadong Medicine Co., Ltd (SZSE:000963)No Data
No Data
